Literature DB >> 9447952

Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients.

J E Henriksen1, F Alford, G M Ward, H Beck-Nielsen.   

Abstract

We tested the hypothesis that glucose intolerance develops in genetically prone subjects when exogenous insulin resistance is induced by dexamethasone (dex) and investigated whether the steroid-induced glucose intolerance is due to impairment of beta-cell function alone and/or insulin resistance. Oral glucose tolerance (OGTT) and intravenous glucose tolerance tests with minimal model analysis were performed before and following 5 days of dex treatment (4 mg/day) in 20 relatives of non-insulin-dependent diabetic (NIDDM) patients and in 20 matched control subjects (age: 29.6 +/- 1.7 vs 29.6 +/- 1.6 years, BMI: 25.1 +/- 1.0 vs 25.1 +/- 0.9 kg/m2). Before dex, glucose tolerance was similar in both groups (2-h plasma glucose concentration (PG): 5.5 +/- 0.2 [range: 3.2-7.0] vs 5.5 +/- 0.2 [3.7-7.4] mmol/l). Although insulin sensitivity (Si) was significantly lower in the relatives before dex, insulin sensitivity was reduced to a similar level during dex in both the relatives and control subjects (0.30 +/- 0.04 vs 0.34 +/- 0.04 10(-4) min(-1) per pmol/l, NS). During dex, the variation in the OGTT 2-h PG was greater in the relatives (8.5 +/- 0.7 [3.9-17.0] vs 7.5 +/- 0.3 [5.7-9.8] mmol/l, F-test p < 0.05) which, by inspection of the data, was caused by seven relatives with a higher PG than the maximal value seen in the control subjects (9.8 mmol/l). These "hyperglycaemic" relatives had diminished first phase insulin secretion (O1) both before and during dex compared with the "normal" relatives and the control subjects (pre-dex O1: 12.6 +/- 3.6 vs 26.4 +/- 4.2 and 24.6 +/- 3.6 (p < 0.05), post-dex O1: 22.2 +/- 6.6 vs 48.0 +/- 7.2 and 46.2 +/- 6.6 respectively (p < 0.05) pmol x l(-1) x min(-1) per mg/dl). However, Si was similar in "hyperglycaemic" and "normal" relatives before dex (0.65 +/- 0.10 vs 0.54 +/- 0.10 10(-4) x min(-1) per pmol/l) and suppressed similarly during dex (0.30 +/- 0.07 vs 0.30 +/- 0.06 10(-4) x min(-1) per pmol/l). Multiple regression analysis confirmed the unique importance of low pre-dex beta-cell function to subsequent development of high 2-h post-dex OGTT plasma glucose levels (R2 = 0.56). In conclusion, exogenous induced insulin resistance by dex will induce impaired or diabetic glucose tolerance in those genetic relatives of NIDDM patients who have impaired beta-cell function (retrospectively) prior to dex exposure. These subjects are therefore unable to enhance their beta-cell response in order to match the dex-induced insulin resistant state.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447952     DOI: 10.1007/s001250050847

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

Review 1.  Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.

Authors:  M K Cavaghan; D A Ehrmann; K S Polonsky
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

3.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

Review 4.  Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale.

Authors:  Moro O Salifu; Fasika Tedla; Serhat Aytug; Amir Hayat; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

5.  Risk factors for corticosteroid-induced hyperglycemia requiring insulin therapy in hospitalized patients without diabetes.

Authors:  Catherine Li; Patricia Krause; Gretchen Stern
Journal:  Endocrine       Date:  2021-04-19       Impact factor: 3.633

Review 6.  Challenges in the diagnosis and management of new-onset diabetes after transplantation.

Authors:  Moro O Salifu; Fasika Tedla; Preethi V Murty; Serhat Aytug; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

7.  A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes.

Authors:  Joseph El Youssef; Jessica R Castle; Deborah L Branigan; Ryan G Massoud; Matthew E Breen; Peter G Jacobs; B Wayne Bequette; W Kenneth Ward
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

8.  Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation.

Authors:  H A Chakkera; R L Hanson; S M Raza; J K DiStefano; M P Millis; R L Heilman; D C Mulligan; K S Reddy; M J Mazur; K Hamawi; A A Moss; K L Mekeel; J R Cerhan
Journal:  Transplant Proc       Date:  2009-12       Impact factor: 1.066

9.  Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.

Authors:  Eric J Chow; Catherine Pihoker; Debra L Friedman; Stephanie J Lee; Jeannine S McCune; Claire Wharton; Christian L Roth; K Scott Baker
Journal:  Pediatr Blood Cancer       Date:  2012-10-05       Impact factor: 3.167

Review 10.  Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.

Authors:  Muhammad Amin; Naeti Suksomboon
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.